BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Zhang SP, Wang Z, Wang LX, Liu SJ. AG490: An inhibitor of hepcidin expression in vivoWorld J Gastroenterol 2011; 17(45): 5032-5034 [PMID: 22174555 DOI: 10.3748/wjg.v17.i45.5032]
URL: https://www.wjgnet.com/1007-9327/full/v17/i45/5032.htm
Number Citing Articles
1
Cadiele Oliana Reichert, Joel da Cunha, Débora Levy, Luciana Morganti Ferreira Maselli, Sérgio Paulo Bydlowski, Celso Spada. Genetic Polymorphisms2017;  doi: 10.5772/intechopen.69507
2
Nicole L. Blanchette, David H. Manz, Frank M. Torti, Suzy V. Torti. Modulation of hepcidin to treat iron deregulation: potential clinical applicationsExpert Review of Hematology 2016; 9(2): 169 doi: 10.1586/17474086.2016.1124757
3
Bart J. Crielaard, Twan Lammers, Stefano Rivella. Targeting iron metabolism in drug discovery and deliveryNature Reviews Drug Discovery 2017; 16(6): 400 doi: 10.1038/nrd.2016.248
4
Shilpa Rana, Nirmal Prabhakar. Iron disorders and hepcidinClinica Chimica Acta 2021; 523: 454 doi: 10.1016/j.cca.2021.10.032
5
Jolanta Malyszko, Jacek S. Malyszko, Joanna Matuszkiewicz-Rowinska. Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney diseaseExpert Opinion on Therapeutic Targets 2019; 23(5): 407 doi: 10.1080/14728222.2019.1599358
6
Cadiele Oliana Reichert, Joel da Cunha, Débora Levy, Luciana Morganti Ferreira Maselli, Sérgio Paulo Bydlowski, Celso Spada. Hepcidin: Homeostasis and Diseases Related to Iron MetabolismActa Haematologica 2017; 137(4): 220 doi: 10.1159/000471838
7
Zorislava Bajić, Nenad Ponorac, Amela Matavulj. The role of hepcidin in iron metabolism in athletesFizicka kultura 2019; 73(2): 206 doi: 10.5937/fizkul1902206B
8
Natalia Murawska, Adam Fabisiak, Jakub Fichna. Anemia of Chronic Disease and Iron Deficiency Anemia in Inflammatory Bowel DiseasesInflammatory Bowel Diseases 2016; 22(5): 1198 doi: 10.1097/MIB.0000000000000648
9
Susana Conde Diez, Ricardo de las Cuevas Allende, Eulogio Conde García. Estado actual del metabolismo del hierro: implicaciones clínicas y terapéuticasMedicina Clínica 2017; 148(5): 218 doi: 10.1016/j.medcli.2016.10.047
10
Wenli Guo, Shuping Zhang, Yue Chen, Daoqiang Zhang, Lin Yuan, Haibo Cong, Sijin Liu. An important role of the hepcidin–ferroportin signaling in affecting tumor growth and metastasisActa Biochimica et Biophysica Sinica 2015; 47(9): 703 doi: 10.1093/abbs/gmv063
11
Ningning Zhao, An-Sheng Zhang, Caroline A. Enns. Iron regulation by hepcidinJournal of Clinical Investigation 2013; 123(6): 2337 doi: 10.1172/JCI67225
12
Wei-Na Kong, Guofen Gao, Yan-Zhong Chang. Hepcidin and sports anemiaCell & Bioscience 2014; 4(1) doi: 10.1186/2045-3701-4-19
13
Jelena Damm, Lois May Harden, Rüdiger Gerstberger, Joachim Roth, Christoph Rummel. The putative JAK-STAT inhibitor AG490 exacerbates LPS-fever, reduces sickness behavior, and alters the expression of pro- and anti-inflammatory genes in the rat brainNeuropharmacology 2013; 71: 98 doi: 10.1016/j.neuropharm.2013.03.014
14
Ricardo de las Cuevas Allende, Lucía Díaz de Entresotos, Susana Conde Díez. Anaemia of chronic diseases: Pathophysiology, diagnosis and treatmentMedicina Clínica (English Edition) 2021; 156(5): 235 doi: 10.1016/j.medcle.2020.07.022
15
Maura Poli, Michela Asperti, Paola Ruzzenenti, Maria Regoni, Paolo Arosio. Hepcidin antagonists for potential treatments of disorders with hepcidin excessFrontiers in Pharmacology 2014; 5 doi: 10.3389/fphar.2014.00086
16
Ricardo de las Cuevas Allende, Lucía Díaz de Entresotos, Susana Conde Díez. Anemia de las enfermedades crónicas: fisiopatología, diagnóstico y tratamientoMedicina Clínica 2021; 156(5): 235 doi: 10.1016/j.medcli.2020.07.035
17
Arielle L. Langer, Yelena Z. Ginzburg. Role of hepcidin-ferroportin axis in the pathophysiology, diagnosis, and treatment of anemia of chronic inflammationHemodialysis International 2017; 21: S37 doi: 10.1111/hdi.12543
18
Fali Zhang, Peng Zhao, Zhongming Qian, Mingkang Zhong. Central Nervous System Inflammation Induced by Lipopolysaccharide Up-Regulates Hepatic Hepcidin Expression by Activating the IL-6/JAK2/STAT3 Pathway in MiceFrontiers in Nutrition 2021; 8 doi: 10.3389/fnut.2021.649640
19
Giada Sebastiani, Nicole Wilkinson, Kostas Pantopoulos. Pharmacological Targeting of the Hepcidin/Ferroportin AxisFrontiers in Pharmacology 2016; 7 doi: 10.3389/fphar.2016.00160
20
Therapeutic potential of hepcidin − the master regulator of iron metabolismPharmacological Research 2017; 115: 242 doi: 10.1016/j.phrs.2016.11.010
21
Stanzin Angmo, Shilpa Rana, Kamalendra Yadav, Rajat Sandhir, Nitin Kumar Singhal. Novel Liposome Eencapsulated Guanosine Di Phosphate based Therapeutic Target against Anemia of InflammationScientific Reports 2018; 8(1) doi: 10.1038/s41598-018-35992-2
22
Zachary J. Hawula, Daniel F. Wallace, V. Nathan Subramaniam, Gautam Rishi. Therapeutic Advances in Regulating the Hepcidin/Ferroportin AxisPharmaceuticals 2019; 12(4): 170 doi: 10.3390/ph12040170
23
Susana Conde Diez, Ricardo de las Cuevas Allende, Eulogio Conde García. Current status of iron metabolism: Clinical and therapeutic implicationsMedicina Clínica (English Edition) 2017; 148(5): 218 doi: 10.1016/j.medcle.2017.03.001
24
Jing Liu, Bingbing Sun, Huijun Yin, Sijin Liu. HepcidinMedicine 2016; 95(14): e3150 doi: 10.1097/MD.0000000000003150
25
Francisca Alcayaga-Miranda, Jimena Cuenca, Maroun Khoury. Antimicrobial Activity of Mesenchymal Stem Cells: Current Status and New Perspectives of Antimicrobial Peptide-Based TherapiesFrontiers in Immunology 2017; 8 doi: 10.3389/fimmu.2017.00339
26
Erin Gaffney-Stomberg, James P. McClung. Inflammation and diminished iron statusCurrent Opinion in Clinical Nutrition and Metabolic Care 2012; 15(6): 605 doi: 10.1097/MCO.0b013e328357f63b
27
Yelena Z. Ginzburg. Iron Metabolism: HepcidinVitamins and Hormones 2019; 110: 17 doi: 10.1016/bs.vh.2019.01.002